£459K
The grant from Innovate UK is matched by recent seed backing from LifeArc, Parkwalk and UKI2S.
I
Ikarovec
Developer of novel gene therapies for major ophthalmic indications.
Norwich, UK—Founded 2019
£3.0MTotal raised
Ikarovec is developing novel and differentiated gene therapies for major ophthalmic indications. The company builds on intellectual property spun out from Quethera.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Current assets
Members only
Cash, assets and headcount from Ikarovec's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
PW
Peter Widdowson
Chief Scientific Officer
Investors
- £459K
- £2.5M
Funding history
£2.5M
The funding round was led by UK Innovation & Science Seed Fund with participation from LifeArc and Parkwalk.